Antihyperlipidemic - PCSK9 Inhibitors

Antihyperlipidemic PCSK9 inhibitors are a class of lipid-lowering therapeutics designed to significantly reduce circulating low-density lipoprotein cholesterol

Antihyperlipidemic PCSK9 inhibitors are a class of lipid-lowering therapeutics designed to significantly reduce circulating low-density lipoprotein cholesterol By preserving these receptors on the hepatocyte surface, the drugs markedly enhance receptor recycling and accelerate the clearance of low-density lipoprotein particles from the bloodstream Clinically, this class is utilized alongside diet and maximally tolerated statin therapy to manage primary hyperlipidemia, treat heterozygous and homo...

These agents function by blocking or suppressing proprotein convertase subtilisin/kexin type 9, preventing it from targeting hepatic low-density lipoprotein receptors for lysosomal degradation

These agents function by blocking or suppressing proprotein convertase subtilisin/kexin type 9, preventing it from targeting hepatic low-density lipoprotein receptors for lysosomal degradation

By preserving these receptors on the hepatocyte surface, the drugs markedly enhance receptor recycling and accelerate the clearance of low-density lipoprotein particles from the bloodstream

Clinically, this class is utilized alongside diet and maximally tolerated statin therapy to manage primary hyperlipidemia, treat heterozygous and homozygous familial hypercholesterolemia, and reduce the risk of major adverse cardiovascular events in individuals with established atherosclerotic cardiovascular disease